By analyzing existing fundamental indicators between Oncosec Medical and Csl, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Csl with a short position in Oncosec Medical. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
One of the ways to look at asset utilization of Oncosec is to check how much profit was generated for every dollar of assets it reports. Oncosec Medical holds a negative application of assets of -55.59 pct., losing $0.56 for each dollar of assets held by the company. Inadequate asset utilization implies the company is being less effective with each dollar of assets it holds. Put it differently, asset utilization of Oncosec Medical shows how discouraging it operates for each dollar spent on its assets.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as OncoSec or ZyVersa is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is OncoSec Medical's Liquidity
OncoSec Medical
financial leverage refers to using borrowed capital as a funding source to finance OncoSec Medical ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. OncoSec Medical financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to OncoSec Medical's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of OncoSec Medical's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between OncoSec Medical's total debt and its cash.
Correlation Between OncoSec and ZyVersa Therapeutics
In general, Delisted Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding OncoSec Medical together with similar or unrelated positions with a negative correlation. For example, you can also add ZyVersa Therapeutics to your portfolio. If ZyVersa Therapeutics is not perfectly correlated to OncoSec Medical it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When OncoSec Medical, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both OncoSec Medical and ZyVersa Therapeutics in your portfolio? Please note if you are using this as a pair-trade strategy between OncoSec Medical and ZyVersa Therapeutics, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between ONCS and ZVSA for more information.
Is OncoSec Medical valued wisely by the market?
Cash and Equivalents Breakdown
Let me take a closer look at Oncosec Medical cash and equivalents. In accordance with the recently published financial statements, Oncosec Medical has 54.39
M in Cash and Equivalents. This is much higher than that of the Healthcare sector and significantly higher than that of the
Biotechnology industry. The cash and equivalents for all United States stocks is notably lower than that of the entity. As for Csl we see cash and equivalents of 2.43
B, which is much higher than that of the Biotechnology
| ONCS | 54.39 Million | 2.19 |
| Sector | 0.0 | 0.0 |
| CSLLY | 2.43 Billion | 97.81 |
Will Oncosec retail investors exit after the fall?
The total risk alpha is down to -1.07 as of today. Oncosec Medical exhibits very low volatility with skewness of -0.34 and kurtosis of -0.38. However, we advise investors to further study Oncosec Medical technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Oncosec Medical's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Oncosec Medical's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
While many of the other players in the biotechnology industry are either recovering or due for a correction, Oncosec Medical may not be performing as strong as the other in terms of long-term growth potentials. The inconsistency in the assessment between current Oncosec valuation and our trade advice on Oncosec Medical is due to the recent market swings and your selection of investing horizon. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Oncosec Medical.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Ellen Johnson is a Member of Macroaxis Editorial Board. Ellen covers public companies in North America, focusing primarily on valuation and volatility. Six years of experience in predictive investment analytics and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of OncoSec Medical. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
[email protected]
